Paul Lizzul F.'s most recent trade in AnaptysBio Inc was a trade of 8,525 Restricted Stock Unit done . Disclosure was reported to the exchange on Jan. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 8,525 | 25,575 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 8,525 | 45,738 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.71 per share. | 07 Jan 2026 | 3,650 | 42,088 (0%) | 0% | 44.7 | 163,192 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 29,000 | 29,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 21,400 | 21,400 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 6,145 | 6,145 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 6,145 | 39,448 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.11 per share. | 06 Jan 2026 | 2,235 | 37,213 (0%) | 0% | 45.1 | 100,821 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2026 | 10,555 | 37,522 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2026 | 10,555 | 21,110 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.26 per share. | 03 Jan 2026 | 4,219 | 33,303 (0%) | 0% | 43.3 | 182,514 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2025 | 1,500 | 83,500 | - | - | Employee Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 22 Dec 2025 | 1,500 | 26,967 (0%) | 0% | 50 | 75,000 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 22 Dec 2025 | 1,500 | 28,467 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 97,200 | 97,200 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 34,100 | 34,100 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,555 | 31,665 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,555 | 26,095 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 6,145 | 12,290 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 6,145 | 27,904 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 4,336 | 21,759 (0%) | 0% | 14.6 | 63,306 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 2,261 | 25,643 (0%) | 0% | 15.3 | 34,593 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.67 per share. | 23 Sep 2024 | 1,500 | 15,398 (0%) | 0% | 38.7 | 58,005 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 23 Sep 2024 | 1,500 | 16,898 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 1,500 | 85,000 | - | - | Common | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 17,618 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 14 Sep 2024 | 2,220 | 15,398 (0%) | 0% | 38.9 | 86,425 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 14 Aug 2024 | 2,000 | 13,618 (0%) | 0% | 18.5 | 37,000 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 2,000 | 86,500 | - | - | Common | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Aug 2024 | 2,000 | 11,618 (0%) | 0% | 40 | 80,000 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 50,000 | 50,000 | - | - | Common Stock | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 18 Jul 2024 | 1,500 | 11,618 (0%) | 0% | 35 | 52,500 | Common Stock |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 1,500 | 88,500 | - | - | Common | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 18 Jul 2024 | 1,500 | 13,118 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| AnaptysBio Inc | Lizzul F. Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 6,145 | 18,435 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Lizzul Paul F. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 6,145 | 12,672 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | Paul Lizzul F. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 2,554 | 10,118 (0%) | 0% | 21.8 | 55,703 | Common Stock |
| AnaptysBio Inc | Lizzul Paul F. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 115,540 | 115,540 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 42,220 | 42,220 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 67,070 | 67,070 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 24,580 | 24,580 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 22.03 per share. | 15 Nov 2021 | 964 | 964 (0%) | 0% | 22.0 | 21,237 | Common Stock |